MedStar Georgetown Transplant Institute, Georgetown University Hospital, Washington, District of Columbia.
Gastroenterology Surgical Center, Department of Surgery, Mansoura University, Mansoura, Egypt.
Am J Transplant. 2019 Jul;19(7):2077-2091. doi: 10.1111/ajt.15269. Epub 2019 Mar 26.
There is a paucity of data on long-term outcomes following visceral transplantation in the contemporary era. This is a single-center retrospective analysis of all visceral allograft recipients who underwent transplant between November 2003 and December 2013 with at least 3-year follow-up data. Clinical data from a prospectively maintained database were used to assess outcomes including patient and graft survival. Of 174 recipients, 90 were adults and 84 were pediatric patients. Types of visceral transplants were isolated intestinal transplant (56.3%), combined liver-intestinal transplant (25.3%), multivisceral transplant (16.1%), and modified multivisceral transplant (2.3%). Three-, 5-, and 10-year overall patient survival was 69.5%, 66%, and 63%, respectively, while 3-, 5-, and 10-year overall graft survival was 67%, 62%, and 61%, respectively. In multivariable analysis, significant predictors of survival included pediatric recipient (P = .001), donor/recipient weight ratio <0.9 (P = .008), no episodes of severe acute rejection (P = .021), cold ischemia time <8 hours (P = .014), and shorter hospital stay (P = .0001). In conclusion, visceral transplantation remains a good option for treatment of end-stage intestinal failure with parenteral nutritional complications. Proper graft selection, shorter cold ischemia time, and improvement of immunosuppression regimens could significantly improve the long-term survival.
关于当代内脏移植后长期结局的数据很少。这是一项对 2003 年 11 月至 2013 年 12 月期间接受移植且至少有 3 年随访数据的所有内脏移植物受者进行的单中心回顾性分析。使用前瞻性维护的数据库中的临床数据来评估包括患者和移植物存活率在内的结局。在 174 名受者中,90 名是成人,84 名是儿科患者。内脏移植的类型为孤立性肠移植(56.3%)、联合肝肠移植(25.3%)、多脏器移植(16.1%)和改良多脏器移植(2.3%)。3 年、5 年和 10 年的总体患者存活率分别为 69.5%、66%和 63%,而 3 年、5 年和 10 年的总体移植物存活率分别为 67%、62%和 61%。多变量分析显示,存活的显著预测因素包括儿科受者(P=0.001)、供体/受者体重比<0.9(P=0.008)、无严重急性排斥反应发作(P=0.021)、冷缺血时间<8 小时(P=0.014)和较短的住院时间(P=0.0001)。总之,内脏移植仍然是治疗伴有肠外营养并发症的终末期肠衰竭的良好选择。适当的移植物选择、缩短冷缺血时间和改善免疫抑制方案可以显著提高长期存活率。